These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics. Luethi D; Liechti ME Int J Neuropsychopharmacol; 2018 Oct; 21(10):926-931. PubMed ID: 29850881 [TBL] [Abstract][Full Text] [Related]
25. Psychedelic-inspired drug discovery using an engineered biosensor. Dong C; Ly C; Dunlap LE; Vargas MV; Sun J; Hwang IW; Azinfar A; Oh WC; Wetsel WC; Olson DE; Tian L Cell; 2021 May; 184(10):2779-2792.e18. PubMed ID: 33915107 [TBL] [Abstract][Full Text] [Related]
26. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform. Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045 [TBL] [Abstract][Full Text] [Related]
30. Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice. de la Fuente Revenga M; Shah UH; Nassehi N; Jaster AM; Hemanth P; Sierra S; Dukat M; González-Maeso J ACS Chem Neurosci; 2021 Mar; 12(5):831-844. PubMed ID: 33400504 [TBL] [Abstract][Full Text] [Related]
31. Use of the head-twitch response to investigate the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines. Halberstadt AL; Luethi D; Hoener MC; Trachsel D; Brandt SD; Liechti ME Psychopharmacology (Berl); 2023 Jan; 240(1):115-126. PubMed ID: 36477925 [TBL] [Abstract][Full Text] [Related]
32. Psychedelics and the human receptorome. Ray TS PLoS One; 2010 Feb; 5(2):e9019. PubMed ID: 20126400 [TBL] [Abstract][Full Text] [Related]
33. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Schmid CL; Raehal KM; Bohn LM Proc Natl Acad Sci U S A; 2008 Jan; 105(3):1079-84. PubMed ID: 18195357 [TBL] [Abstract][Full Text] [Related]
34. Towards a quantitative representation of the cell signaling mechanisms of hallucinogens: measurement and mathematical modeling of 5-HT1A and 5-HT2A receptor-mediated ERK1/2 activation. Chang CW; Poteet E; Schetz JA; Gümüş ZH; Weinstein H Neuropharmacology; 2009; 56 Suppl 1(Suppl 1):213-25. PubMed ID: 18762202 [TBL] [Abstract][Full Text] [Related]
35. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT Åstrand A; Guerrieri D; Vikingsson S; Kronstrand R; Green H Forensic Sci Int; 2020 Dec; 317():110553. PubMed ID: 33160102 [TBL] [Abstract][Full Text] [Related]
36. Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor. Deventer MH; Persson M; Laus A; Pottie E; Cannaert A; Tocco G; Gréen H; Stove CP Arch Toxicol; 2023 May; 97(5):1367-1384. PubMed ID: 36853332 [TBL] [Abstract][Full Text] [Related]